Risperidone LA is under clinical development by Nanomi and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Risperidone LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Risperidone LA overview

Risperidone is under development for the treatment of schizophrenia. It is administered through intramuscular route and acts by targeting 5-hydroxytryptamine receptor 2A (5 HT2A) and D2 dopamine receptor (DRD2).

Nanomi overview

Nanomi, a subsidiary of Lupin Ltd, is a drug delivery company. It manufactures and develops microspheres and nanoparticles. The company utilizes Microsieve, a proprietary micro-filtration technology to produce its products. Its products are used in encapsulation of various injectables and pharmaceutical compounds such as antibodies, hormones, small molecules and cytostatic compounds. Nanomi is headquartered in Oldenzaal, Overijssel, the Netherlands.

For a complete picture of Risperidone LA’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 15 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.